Animal studies have unequivocably shown that removing visceral or "belly" fat, that fat within the abdominal cavity, has an immediate, substantial and permanent beneficial effect upon their metabolism.
Prior to BioSculpture Technology, Inc.'s patented method and device it was never clinically feasible to safely and efficiently remove mesenteric fat, the fat in the supportative tether of bowel. Human studies have been directed at removing the omentum, the fatty apron hanging down from the stomach. Omentectomy has an additive effect when performed in association with gastric banding but has resulted in inconsistent improvement when performed as an accompaniment to gastric bypass. Explanations for this inconsistency have centered on either the incompleteness of omentectomy, the amount of small bowel bypassed in a roux-en-Y, or the resistin-abating effect simply having been "maxed out" because there is a shared reason for the efficacy of either modality. However mesenteric fat may be even more dangerous than omental fat as its involvement with diseases such as Crohn's suggests.
An inference may be drawn that mesenteric fat is much more metabolically significant than omental fat given mesenteric fat's more vascular appearance, richer lymphatic connections and portal proximity. Research studies have supported this inference. Narrowing of the carotid arteries has a straight line correlation with thickening of the small bowel mesentery with fat, in other words the thicker the mesentery, the thicker is the intimal wall of the carotid and the less room for blood flow, increasing the chance of strokes and transient ischemic attacks. An analysis of clinically removed fat as clinical studies of visceral lipectomy are carried out will enable us to confirm this as well as show us the spots in the mesentery (e.g. about the ileum) which are most dangerous. BioSculpture Technology, Inc. has patented methods and devices for both doing so and targetting the most hazardous fat for removal.
Efficacy studies are required both for F.D.A. approval to promote EVL® for obesity treatment and to quantify the precise multiple of body fat that will be lost relative to the relatively small amount of visceral fat that will be removed in each visceral lipectomy procedure. A multiple of 7X or more is expected on the basis of the general ratio of fat distribution existing between the body's fat compartments.
JAMA reported that over 1/3 of the U.S. population has metabolic syndrome. A major risk factor for metabolic syndrome is abdominal obesity. 80% of type 2 diabetics are obese. And diabetes is the leading cause of renal failure requiring dialysis, the reason for over half of amputations performed and a leading cause of blindness. Obesity dosn't just shorten your life, it decreases its quality. And the most deadly location for the fat is in the abdomen, specifically within the mesentery abdomen. Fortunately Endoscopic Visceral Lipectomy has the potential of allowing us to specifically target that most deadly fat for the very first time.
REMOVING THE VISCERAL FAT WHICH KILLS YOU
The 85% of subcutaneous fat you can pinch with your fingers about your middle may be unsightly, but it is the 15% of fat within the abdomen, the visceral or "belly" fat which is responsible for the morbidities of obesity. It is this visceral or "belly" fat which reduces the quality of your life, shortens it, and kills you.
Intra-abdominal fat is a noxious hormone factory, secreting cytokines or cellular hormones which cause diabetes, hypertension, vascular disease, strokes, heart attacks, autoimmune diseases, and cancers. It causes sleep apnea and gastric reflux.
EVL® has been developed for the safe and effective endoscopic removal of visceral fat. Removing visceral fat will not involve cutting into the stomach or bowel, rearranging aliminary plumbing, or leaving behind a foreign body.